# Challenges in implementing the WHO-recommended package of care for advanced HIV disease in resource-constrained settings: A mixed-methods study

**Authors:** Temesgen Leka Lerango, Semalgn Leka Lerango, Mesfin Abebe, Tsion Mulat Tebeje, Habtamu Endashaw Hareru, Daniel Sisay, Getachew Assefa Zenebe, Yohannes Addisu, Biruk Bogale, Felix Bongomin, Felix Bongomin, Felix Bongomin

PMC · DOI: 10.1371/journal.pone.0341162 · PLOS One · 2026-01-20

## TL;DR

This study identifies challenges in implementing WHO's HIV care guidelines in Ethiopia, showing inconsistent delivery due to systemic issues like medication shortages and weak referral systems.

## Contribution

The study provides new insights into implementation barriers of WHO HIV care guidelines in resource-limited settings through mixed-methods analysis in Southern Ethiopia.

## Key findings

- Only 47.6% of AHD cases had baseline CD4 testing, and 20% initiated ART rapidly.
- Structural, service delivery, and patient-related challenges hindered WHO package implementation.
- Medication shortages and lack of dedicated AHD clinics were major systemic barriers.

## Abstract

People diagnosed with advanced HIV disease (AHD) should be provided with the World Health Organization’s (WHO) package of care to address their specific healthcare needs. Although the WHO-recommended package of care is considered feasible and effective, its implementation remains sub-optimal across many sub-Saharan African (SSA) countries. This study aimed to explore challenges in implementing the WHO-recommended package of care for advanced HIV disease in resource-constrained settings.

A sequential explanatory mixed-methods study was conducted between March 1 and April 30, 2024, in the Gedeo Zone of Southern Ethiopia. The quantitative data involved extraction from medical records of 145 individuals newly diagnosed with AHD. For the qualitative inquiry, healthcare providers engaged in the HIV care continuum were purposively selected for in-depth key informant interviews. An inductive thematic analysis was conducted to identify and interpret recurrent patterns within the qualitative data. Quantitative data were analyzed using R version 4.3.3, while qualitative data were organized and managed using NVivo version 14.

Only about half (47.6%) of the newly diagnosed AHD cases underwent baseline CD4 count testing. All 145 individuals were screened for TB using the WHO four-symptom algorithm, and 78.6% underwent confirmatory GeneXpert® MTB/RIF testing. Among individuals with AHD, 92.4% received co-trimoxazole prophylaxis, and 14.5% received tuberculosis preventive therapy. Rapid ART initiation was implemented for 20.0% of individuals with AHD. All newly diagnosed individuals with AHD received tailored counseling to ensure optimal adherence. Qualitative data analysis identified three principal challenges to the implementation of the WHO-recommended package of care: structural and organizational obstacles, service delivery constraints, and patient-related concerns as expressed by healthcare workers.

The implementation of the WHO-recommended package of care for individuals with AHD remains inconsistent. Although adherence support is routinely offered to all newly diagnosed individuals with AHD, the delivery of other key components is frequently hindered by a range of systemic challenges. These include the unavailability or frequent stockouts of essential medications and services for managing opportunistic infections, weak referral and linkage systems, and the absence of dedicated AHD care clinics. Such challenges underscore significant gaps in the continuum of AHD care and highlight the pressing need for targeted, system-level interventions to ensure comprehensive service delivery.

## Linked entities

- **Chemicals:** co-trimoxazole (PubChem CID 358641)
- **Diseases:** tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** tuberculosis (MESH:D014376), TB (MESH:D014390), AHD (MESH:D015658), opportunistic infections (MESH:D009894)
- **Chemicals:** co-trimoxazole (MESH:D015662)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12818689/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12818689/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12818689/full.md

---
Source: https://tomesphere.com/paper/PMC12818689